AN2 Therapeutics Announces $40 Million Private Placement Financing

2026-03-09 16:14:05

Abstract generation in progress

AN2 Therapeutics, a clinical-stage biopharmaceutical company, announced a private placement financing expected to generate approximately $40 million in gross proceeds. The financing includes the sale of common stock and pre-funded warrants to new and existing institutional investors, including Coastlands Capital, Commodore Capital, and Vivo Capital. The proceeds will support the company’s development of novel small molecule therapeutics utilizing its boron chemistry platform.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.